[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100522567":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":34,"responsibleParty":50,"collaborators":53,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":20,"eligibilityCriteria":62,"healthyVolunteers":59,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":20,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":20,"overallStatus":36,"whyStopped":20,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Tongji Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment (autologous tumor infiltrating lymphocytes)","EXPERIMENTAL","Post-NMA lymphodepletion, patients are infused with their autologous TIL followed by IL-2 administration.",[13],"Biological: Autologous Tumor Infiltrating Lymphocytes",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","Autologous Tumor Infiltrating Lymphocytes","Fresh tumor samples will be resected from enrolled patients. Autologous TILs will be extracted and reinfused to corresponding patients after ex vivo stimulation, activation, and extensive expansion.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Zhiyong Huang","PRINCIPAL_INVESTIGATOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"Tong Yuan","CONTACT","86-15071338542","Zyhuang126@126.com",{"name":32,"role":28,"phone":20,"phoneExt":20,"email":33},"Tian Xia","tianxia@hust.edu.cn",[35],{"facility":5,"status":36,"city":37,"state":20,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"RECRUITING","Wuhan","430000","China","CN",{"type":42,"coordinates":43},"Point",[44,45],114.26667,30.58333,{"lat":45,"lon":44},[48,49],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},{"name":32,"role":28,"phone":20,"phoneExt":20,"email":33},{"type":51,"investigatorFullName":23,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"SPONSOR_INVESTIGATOR","Professor",[54],{"name":55,"class":56},"Wuhan Elongevity Technology Co., Ltd.","UNKNOWN","100522567","phase-1-immunotherapy-using-tumor-infiltrating-lymphocytes-for-patients-with-advanced-liver-cancer-100522567",false,"NCT06084299","Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Advanced Liver Cancer","Inclusion Criteria:\n\n* The subjects must be informed of the study before the test and voluntarily sign a written informed consent.\n* Age of the patients was between 18\\~70 years\n* Eligible patients have histologically proven advanced liver cancer\n* Eastern Cooperative Oncology Group (ECOG) performance status was 0-1\n* Metastatic lesions are confirmed by PET-CT, CT, MR and\u002For intraoperative exploration (more than 3, at least one accessible metastasis to procure for TILs)\n* Patients have at least one separate additional measurable tumour lesion according to RECIST version 1.1 standard.\n* The disease has progressed after at least two previous lines of standard treatment and there is no effective treatment option available\n* Adequate normal organ and marrow function were present, including absolute neutrophil count ≥ 1×10\\^9\u002FL, leukocyte count ≥ 3×10\\^9\u002FL, platelet count ≥ 75×10\\^9\u002FL, hemoglobin ≥ 80 g\u002FL, AST and ALT ≤ 2× of upper limit of normal, Serum creatinine ≤ 1.5× upper normal limits, Serum total bilirubin ≤ 1.5× upper normal limits\n* Female subjects of childbearing age must have a negative urine or serum HCG test within 7 days before cell reinfusion\n* Provide at least one gram of fresh tumor tissue and 10ml of peripheral blood for whole exome sequencing and TIL isolation and culture.\n* Expected survival was at least 3 months\n* Child-Push liver function score grade is A within seven days before the cell reinfusion.\n\nExclusion Criteria:\n\n* With previous or concurrent other active cancer (except carcinoma in situ that has been cured without onset within 5 years, or those that can be cured by adequate treatment)\n* Patients with metastasis to Central Nervous System or brain\n* Have received organ transplantation in the past\n* Received major liver surgery within 4 weeks before the first administration (except liver metastases biopsy).\n* Received local treatment of the liver or other parts within 4 weeks before the first administration (transcatheter arterial chemoembolization \\[TACE\\], transcatheter arterial embolization \\[TAE\\], hepatic artery infusion \\[HAI\\], radiotherapy, radioembolization or ablation). Subjects are not eligible to participate in the study if the above-mentioned treatment is carried out between the last dose of sorafenib or oxaliplatin-containing regimen and the first study administration.\n* After CT angiography examination, there is severe arterial embolism or hepatic artery vascular variation.\n* APTT or PT \\>= 5 UNL, or with bleeding evidence in two months or bleeding history in prior to the clinical study, no matter how serious it is\n* Active inflammation within 7 days after systemic antibiotics treatment\n* Subjects who have undergone major surgery or severe trauma such as laparotomy, thoracotomy, and laparoscopic organ removal within 4 weeks before enrollment.\n* Active coronary artery disease, serious or unstable angina pectoris, or newly diagnosed angina pectoris or myocardial infarction within 12 months prior to the clinical study\n* Thrombosis or embolism event within 12 months prior to the clinical study, such as cerebrovascular accident ( including TIA) or pulmonary embolism\n* Congestive heart failure of NYHA \\>= Class II\n* Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), untreated active hepatitis (hepatitis B, defined as HBV-DNA ≥ 500 IU\u002Fml C Hepatitis, defined as HCV-RNA higher than the detection limit of the analytical method) or co-infection with hepatitis B and hepatitis C.\n* Presence of any active, known or suspected autoimmune disease. Subjects in a stable state who do not require systemic immunosuppressive therapy are allowed, such as: type 1 diabetes mellitus, hypothyroidism requiring only hormone replacement therapy, and skin diseases that do not require systemic therapy (e.g., vitiligo, psoriasis disease and hair loss).\n* Any interstitial lung disease, noninfectious causes of lung inflammation, or uncontrolled systemic disease (e.g. diabetes, pulmonary fibrosis, or acute pneumonia)\n* Any adverse event of CTCAE (Ver 5.0) grade 2 or higher induced by previous treatment, except anemia, hair loss, and skin pigmentation\n* Pregnant or lactating women or those who are positive in pregnancy test before 1st injection\n* The investigator believes that the subject has any clinical or laboratory abnormalities or compliance problems and is not suitable for participating in this clinical study.\n* With serious psychological or mental abnormalities\n* Joined other clinical trials in four weeks prior to this study\n* Patients who have a history of hypersensitivity to cyclophosphamide and fludarabine.\n* Other researchers think that they are not suitable for enrollment.","ALL","18 Years","70 Years",{"count":67,"type":68},16,"ESTIMATED","INTERVENTIONAL",[71],"PHASE1","Single-arm, open-label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocytes (TIL) infusion followed by IL-2 after a non-myeloablative(NMA) lymphodepletion preparative regimen for the treatment of patients with advanced liver cancer.",[74],"Liver Cancer","2025-08-14",{"date":77,"type":78},"2025-08-19","ACTUAL",{"date":80,"type":78},"2020-05-27",{"date":82,"type":68},"2026-08-30",{"name":23,"class":6},1]